Industry welcomes EU moves to improve orphan drug access
This article was originally published in SRA
Executive Summary
The biopharmaceutical industry has welcomed moves by the European Commission to set up a new EU rare diseases expert committee with industry representation, and has given its backing to calls for a new body to be established at the European Medicines Agency to assess the added value represented by new orphan drugs1,2.